Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 2 chart positions in 2 markets.
By chart position
- 🇨🇦CA · Science#1845K to 30K
- 🇬🇷GR · Science#118500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
2.8K to 17K🎙 ~2x weekly·137 episodes·Last published 1w ago - Monthly Reach
Unique listeners across all episodes (30 days)
5.5K to 33K🇨🇦91%🇬🇷9% - Active Followers
Loyal subscribers who consistently listen
2.2K to 13K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 10 epsHosts
Recent guests
Recent episodes
Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances
May 23, 2026
Unknown duration
Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances
Apr 20, 2026
58m 54s
CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson
Apr 10, 2026
24m 54s
Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review
Apr 1, 2026
24m 50s
CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson
Mar 23, 2026
24m 29s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 5/23/26 | Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances | Dr Jennifer R Brown and Prof Wojciech Jurczak discuss the selection and sequencing of Bruton tyrosine kinase-targeted therapy for patients with chronic lymphocytic leukemia and summarize major advances in the treatment landscape over the past year.CME information and select publications here. | — | ||||||
| 4/20/26 | Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances✨ | Acute Myeloid Leukemiaclinical trials+3 | Dr Amir FathiDr Eunice S Wang | Massachusetts General HospitalRoswell Park Comprehensive Cancer Center | Boston, MassachusettsBuffalo, New York | Acute Myeloid Leukemiamenin inhibitors+3 | — | 58m 54s | |
| 4/10/26 | CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson✨ | CELMoDsMultiple Myeloma+3 | Dr Paul G Richardson | Dana-Farber Cancer Institute | Boston, Massachusetts | CELMoDsMultiple Myeloma+3 | — | 24m 54s | |
| 4/1/26 | Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review✨ | immune thrombocytopeniaBruton tyrosine kinase inhibitors+3 | Dr Hanny Al-Samkari | Bruton tyrosine kinase inhibitorsBAFF-R antagonists+1 | — | immune thrombocytopeniaBruton tyrosine kinase inhibitors+3 | — | 24m 50s | |
| 3/23/26 | CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson✨ | CELMoDsMultiple Myeloma+3 | Dr Paul G Richardson | Dana-Farber Cancer Institute | Boston, Massachusetts | CELMoDsMultiple Myeloma+3 | — | 24m 29s | |
| 3/21/26 | Immune Thrombocytopenia — Microlearning Activity 3 with Dr Hanny Al-Samkari: ASH 2025 Review✨ | immune thrombocytopeniaBruton tyrosine kinase inhibitors+3 | Dr Hanny Al-Samkari | Bruton tyrosine kinase inhibitorsBAFF-R antagonists+1 | — | immune thrombocytopeniaBruton tyrosine kinase inhibitors+5 | — | 29m 16s | |
| 3/13/26 | CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal Shah✨ | Acute Lymphoblastic LeukemiaBiTEs+3 | Dr Bijal Shah | Moffitt Cancer Center | Tampa, Florida | BiTEsAcute Lymphoblastic Leukemia+3 | — | 1h 03m 21s | |
| 3/11/26 | Chronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Presentations from the 2025 ASH Annual Meeting✨ | Chronic Lymphocytic LeukemiaManagement+3 | Prof Constantine Tam | Monash University | — | Chronic Lymphocytic LeukemiaASH Annual Meeting+3 | — | 47m 10s | |
| 3/9/26 | Immune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH 2025 Review✨ | immune thrombocytopeniaBruton tyrosine kinase inhibitors+3 | Dr Hanny Al-Samkari | Bruton tyrosine kinase inhibitorsBAFF-R antagonists+1 | — | immune thrombocytopeniaBruton tyrosine kinase inhibitors+3 | — | 19m 21s | |
| 3/4/26 | Immune Thrombocytopenia — Microlearning Activity 1 with Dr Hanny Al-Samkari: ASH 2025 Review✨ | immune thrombocytopeniaBruton tyrosine kinase inhibitors+4 | Dr Hanny Al-Samkari | Bruton tyrosine kinase inhibitorsBAFF-R antagonists+1 | — | immune thrombocytopeniaBruton tyrosine kinase inhibitors+4 | — | 24m 25s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 2/18/26 | Multiple Myeloma: Inside the Issue of Cereblon E3 Ligase Modulators✨ | multiple myelomaCereblon E3 ligase modulators+3 | Dr Natalie S CallanderDr Paul G Richardson | CELMoDsUniversity of Wisconsin Carbone Cancer Center+1 | — | multiple myelomaCELMoDs+3 | — | 57m 58s | |
| 2/13/26 | Relapsed/Refractory Multiple Myeloma — Microlearning Activity 2 with Dr Sagar Lonial: ASH 2025 Review | Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.CME information and select publications here. | — | ||||||
| 2/6/26 | Immune Thrombocytopenia — ASH 2025 Review | Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr Cindy Neunert from Columbia University Irving Medical Center in New York and Prof Francesco Zaja from ASUGI in Trieste, Italy discuss cases of immune thrombocytopenia and recent findings from the 2025 ASH Annual Meeting.CME information and select publications here. | — | ||||||
| 2/3/26 | Relapsed/Refractory Multiple Myeloma — Microlearning Activity 1 with Dr Sagar Lonial: ASH 2025 Review | Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.CME information and select publications here. | — | ||||||
| 1/21/26 | Bispecific Antibodies in the Management of Lymphoma — ASH 2025 Review | Prof Michael Dickinson from Peter MacCallum Cancer Centre in Melbourne, Australia, and Dr Laurie H Sehn from the University of British Columbia in Vancouver, Canada, discuss clinical cases and recent findings from the 2025 ASH Annual Meeting relating to the use of bispecific antibodies in the management of lymphoma.CME information and select publications here. | — | ||||||
| 1/16/26 | Relapsed/Refractory Multiple Myeloma — ASH 2025 Review | Dr Sagar Lonial from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr María-Victoria Mateos from the University Hospital of Salamanca in Salamanca, Spain, discuss cases of relapsed/refractory multiple myeloma and recentresearch findings from the 2025 ASH Annual Meeting. CME information and select publications here. | — | ||||||
| 1/13/26 | Follicular Lymphoma and Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition | Dr Nancy L Bartlett from the Washington University School of Medicine, Dr John P Leonard from the Perlmutter Cancer Center, Dr Matthew Matasar from Rutgers Cancer Institute, Dr Loretta J Nastoupil from Southwest Oncology and Prof Pier Luigi Zinzani from the University of Bologna in Italy discuss recent updates on available and novel treatment strategies for follicular lymphoma and diffuse large B-cell lymphoma. CME information and select publications here. | — | ||||||
| 1/9/26 | Myelofibrosis and Systemic Mastocytosis — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition | Prof Claire Harrison from Guy’s and St Thomas’ NHS Foundation Trust in London, Dr Andrew T Kuykendall from Moffitt Cancer Center, Dr Stephen T Oh from the Washington University School of Medicine, Dr Jeanne Palmer from the Mayo Clinic School of Medicine and Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center discuss recent updates on available and novel treatment strategies for myelofibrosis and systemic mastocytosis.CME information and select publications here. | — | ||||||
| 1/7/26 | Chronic Lymphocytic Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition | Dr Matthew S Davids from Dana-Farber Cancer Institute, Dr Bita Fakhri from Stanford University School of Medicine, Prof Constantine Tam from Alfred Health in Melbourne, Australia, and Dr Jennifer Woyach from The Ohio State University Comprehensive Cancer Center review the treatment landscape for patients with chronic lymphocytic leukemia and discuss current research immediately before the 67th ASH Annual Meeting.CME information and select publications here. | — | ||||||
| 1/3/26 | Acute Myeloid Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition | Dr Harry Paul Erba from the Duke Cancer Institute, Dr Amir Fathi from Massachusetts General Hospital, Dr Tara L Lin from The University of Kansas Medical Center, Dr Alexander Perl from the University of Pennsylvania’s Abramson Cancer Center and Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center discuss recent data surrounding the management of AML and their perspectives on clinical application.CME information and select publications here. | — | ||||||
| 12/12/25 | Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Partnership with the American Oncology Network | Dr Kerry A Rogers from The Ohio State University in Columbus summarizes the treatment landscape and reviews relevant clinical datasets for patients with chronic lymphocytic leukemia. CME information and select publications here. | — | ||||||
| 12/11/25 | CAR T-Cell Therapy for Non-Hodgkin Lymphoma | Cancer Q&A — Discussing Common Questions Posed by Patients | Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Loretta J Nastoupil from CommonSpirit Mercy Hospital in Durango, Colorado, discuss the clinical applications of chimeric antigen receptor T-cell therapy for patients with non-Hodgkin lymphoma. CME information and select publications here. | — | ||||||
| 12/4/25 | Toxicities Associated with CAR T-Cell Therapy — An Interview with Dr Matthew Lunning | Dr Matthew Lunning from the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska, discusses recent updates on the management of toxicities associated with CAR T-cell therapy. CME information and select publications here. | — | ||||||
| 11/15/25 | Patient Education Resource: Non-Hodgkin Lymphoma — Clinical Experts Address Common Questions Posed by Patients About CAR T-Cell Therapy | Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Manali Kamdar from the University of Colorado Cancer Center in Aurora discuss patient questions and experiences with CAR T-cell therapy for non-Hodgkin lymphoma. Educational information and select publications here. | — | ||||||
| 11/13/25 | Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute | Dr Matthew Lunning and Dr Sonali M Smith share their perspectives on the evolving therapeutic landscape for patients with diffuse large B-cell lymphoma and follicular lymphoma. CME information and select publications here. | — | ||||||
Showing 25 of 139
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
2 placements across 2 markets.
Chart Positions
2 placements across 2 markets.